api - Profile
US Patents and Regulatory Information for api
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Torrent | APIXABAN | apixaban | TABLET;ORAL | 210156-002 | Dec 17, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | AB | RX | Yes | No | 6,967,208*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Mylan | APIXABAN | apixaban | TABLET;ORAL | 210128-001 | Dec 23, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Impax | APIXABAN | apixaban | TABLET;ORAL | 209810-001 | Feb 14, 2025 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Apotex | APIXABAN | apixaban | TABLET;ORAL | 210091-001 | Feb 16, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Apotex | APIXABAN | apixaban | TABLET;ORAL | 210091-002 | Feb 16, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Accord Hlthcare | APIXABAN | apixaban | TABLET;ORAL | 210180-002 | Jul 28, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
